Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer's Disease Using Immunomagnetic Reduction
Related Experiment Video
Updated: Oct 20, 2025
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
Huei-Chun Liu1, Hsin-Hsien Chen1, Chia-Shin Ho1
1MagQu Co., Ltd., New Taipei City, 231, Taiwan.
Introduction:
Concentrations of plasma biomarkers associated with Alzheimer's disease have been reported to be as low as several tens of picograms/milliliter (pg/ml). However, in assays measuring these biomarkers, it is likely that repeated measurements are necessary to obtain reliable values.
Methods:
We performed assays as a single test or as duplicate, quadruplicate, fivefold and tenfold repeated tests, on samples spiked with different concentrations of amyloid β 1-40 (Aβ1-40; 1-1000 pg/ml), Aβ1-42 (1-30,000 pg/ml) and total Tau protein (T-Tau; 0.1-1000 pg/ml), with the aim to to calculate the coefficients of variation (CVs).
Results:
The results demonstrated common changes in the CVs with changes in the number of tests for a given sample: the CVs decreased with increases in the number of tests from one to ten. All CV values were distributed within the range of 0.35 to 15.5%; as such, the CV values were all lower than the acceptable value of 20%.
Conclusion:
Based on this study, a single assay of Aβ1-40, Aβ1-42 and T-Tau, respectively, provides reliable results in terms of the measurement of that plasma biomarker.
